Irritable Bowel Syndrome Drugs Industry - Regional Synopsis
The North American irritable bowel syndrome drugs market is set to dominate majority revenue share by the end of 2037. The market growth can be attributed to the increasing frequency of fecal incontinence and the availability of efficient treatment options in the region. For instance, 50 to 70 patients out of every 100 nursing home residents and 18 to 33 patients out of every 100 hospitalized patients, respectively, suffer from fecal incontinence. Fecal incontinence affects 7 to 15 persons out of every 100 who are not patients or residents of nursing homes or hospitals. In addition, the region's supportive health policies and expanding healthcare industry are anticipated to boost the market expansion.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Irritable Bowel Syndrome Drugs Market in 2025 is estimated at USD 4.43 billion.
The global market size was around USD 4.14 billion in 2024 and is likely to expand at a CAGR of more than 8.7%, surpassing USD 12.25 billion revenue by 2037.
North America takes the lead, driven by fecal incontinence treatment needs and efficient care options.
The major players in the market include Abbott Services, Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Ironwood Pharmaceuticals, Inc., Synergy Pharma Consultancy Private Limited, Synthetic Biologics, Inc.
